Spago Nanomedical Board Seeks Nasdaq First North Delisting, Subject to Shareholder Approval

Bitget2026/10/22 17:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Spago Nanomedical’s board resolved to seek delisting from Nasdaq First North Growth Market, subject to shareholder approval.
The board convened an extraordinary general meeting for November 19, 2026; shareholders representing approximately 65% of shares and votes intend to support delisting.
Delisting aims to attract specialist investors to finance Tumorad’s planned Phase IIa trial, with listed-market funding deemed unavailable on acceptable terms.
The application is planned no earlier than January 25, 2027, with final trading expected in February 2027, subject to Nasdaq Stockholm approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spago Nanomedical AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Spago Nanomedical Board Seeks Nasdaq First North Delisting, Subject to Shareholder Approval

You may also like

Crypto prices